
Thursday, October 31, 2024 10:49:07 AM
A study, not sponsored by ENDV, but using the Sofpulse by Christine Rhode, produced no noticeable advantages of using Sofpulse after mastectomy procedure.
Ilfeld's study might be the last saving spark ENDV needs to stay alive.
Recent ENDV News
- Form SEC STAFF ACTION - SEC Staff Action: ORDER • Edgar (US Regulatory) • 09/19/2024 07:00:01 PM
UAV Corp. to Present Critical Inflation Test in 30 Days, Paving the Way to Secure Over $525 Million in DART Series Sales Contracts • UMAV • Mar 14, 2025 1:00 PM
Fifty 1 Labs, Inc. Completes Name and Symbol Change, Advances Toward Regaining 15c211 Compliance • FITY • Mar 14, 2025 10:30 AM
WIN-LIGHT GLOBAL FILES SEC SCHEDULE 13G DISCLOSING 1.96M SHARES OF PASSIVE INSTITUTIONAL INVESTOR OWNERSHIP • CNTM • Mar 14, 2025 7:13 AM
The Crypto Company Expands Leadership Team With Experienced Financial and Blockchain Professionals • CRCW • Mar 13, 2025 9:23 AM
ConnectM Announces $10 Million Share Repurchase Program • CNTM • Mar 13, 2025 9:13 AM
Sigyn CEO Note: An Emerging New Industry, 15 Years in the Making • SIGY • Mar 12, 2025 9:41 AM